Endo News Roundup: Managing HbA1c & CV Risks

September 15, 2016

New studies highlight which T2DM meds help reduce CV risks and, for metformin failure, the benefits of early intervention & a promising drug combo.

T2DM patients who take gliptins or glitazones may have decreased risks of heart failure, cardiovascular disease, and all-cause mortality. Early intervention in T2DM patients who fail metformin monotherapy can lead to rapid attainment of HbA1c goals. Insulin glargine plus the glucose-lowering agent lixisenatide complement each other and lead to clinically meaningful HbA1c reductions in T2DM more than either drug alone.

Gliptins and Glitazones Decrease Cardiac Risks. Abstract link.

T2DM patients who take glitazones or gliptins alone or in combination tend to have lower CV risks.

Gliptins/glitazones study results

Intensify Therapy for Metformin Failures. Abstract link.

Intensification of therapy after metformin failure can help patients reach HbA1c goals.

Metformin therapy intensification study results

Two-Drug Combo Redules HbA1c in Metformin Failure. Abstract link.

A combination of insulin glargine and lixisenatide reduces HbA1c significantly more than either drug given separately in T2DM patients who are inadequately controlled on metformin.

Insulin glargine-lixisenatide study results

Take-home Messages

Related Content:

Endo News Roundup: Managing HbA1c & CV Risks

Mark L. Fuerst